Resistance to Artemisinin-Based Combination Therapies (ACTs) Among Patients: Challenges and Strategic Approaches for Mitigation
DOI:
https://doi.org/10.5281/Keywords:
ACTs resistance, Patient, Malaria parasites, Antibiotics, Plasmodium falciparumAbstract
Artemisinin resistance delayed parasite clearance following treatment with conventional ACT regimens. This may result from poor drug compliance on the patient’s part, poor quality of the drug or patient re-exposure to the parasite. The study investigated the rate of ACT resistance among patients and possible approaches to combat it. The study adopted a descriptive cross-sectional study design and laboratory examination of patients’ blood for malaria parasites. The questionnaire was used to elicit data from 2,720 respondents and 70 participants were used for the laboratory blood test using rapid test kits. Data were analyzed using descriptive statistics.
The study showed that 1,397 (51.36%) were females and 1,160 (42.65%) were males with prescriptions based on hospital visits from March 2020 to July 2021. The majority 820 (30.45%) were within the age bracket of 21-30 years. The various dosage forms observed were IM injections, tablet forms and some pediatrics suspensions. Co-prescribed antibiotic drug ciprofloxacin 176 (23.31%) as mostly prescribed, Azithromycin followed with a frequency of 132 (17.48%), with clarithromycin 8 (1.06%) having the lowest frequency. There is evidence of ACT resistance among patients used in the study. Irrespective of the type of ACT prescribed, there are usually resistances due to factors like non-completion of treatment, poor quality of the ACT, and re-exposure to the parasite. It is recommended that patients should be encouraged to complete their treatment, prescribers should always check for the efficacy of the ACT before making it available to patients and non-pharmaceutical approaches should be encouraged to avoid re-exposure to the parasite.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 J. J. Etim, O. S. Efegene, J. M. Ibu, E. I. Ekpo, C. C. Otali, O. J. Etim-John, N. N. Agbiji, I. E. Idem (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.
Permissible Uses and Attribution
- Citation: Any use or reproduction of content from EMSAJ Publishing Global journals must include the customary bibliographic citation, including author attribution, date, and article title.
- Permission: For commercial use or reproduction beyond fair use guidelines, explicit permission must be obtained from EMSAJ Publishing Global or the copyright holder.